The Aplastic Anemia & Myelodysplasia Association of Canada (AAMAC) is developing a submission for the pan-Canadian Oncology Drug Review (pCODR) for (orally administered/tablets) decitabine and cedazuridine (INQOVI) for the treatment of patients with Myelodysplastic Syndrome (MDS).
note: decitabine and cedazuridine (INQOVI) tablets were formerly known as "ASTX727"
MDS is a severe, chronic syndrome. It often progresses to Acute Myeloid Leukemia, which is a type of cancer of the blood and bone marrow. 
We are specifically seeking input from patients with experience with  treatments for MDS including oral decitabine (INQOVI). 

Your insights and experience will help guide the pan-Canadian Oncology Drug Review - an evidence-based, cancer drug review process designed to inform Canada's provinces and territories* in guiding their drug funding decisions. 

This survey will take  approximately 12 minutes to complete. We ask that you complete the survey by October  1. 
Note: Respondents should not use browser navigation buttons to move through the survey. Please use the "Previous" and "Next" buttons to move through the survey. 

If you have any questions about this survey, please write to us at and include "Patient and Caregiver Survey" in the subject line of the email.

Privacy Policy: All survey data is being collected by AAMAC, a charitable patient-led support and advocacy group registered with pCODR. To ensure patient privacy and confidentiality, individual responses will not be identifiable. Although selected quotations may be used for the final submission to government agencies, no reference to patient name or any other identifying information will be included.

Thank you for your participation!
* Outside of Quebec, which is managed by the Institut National d’Excellence en Santé et Services sociaux.